Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.16 USD | +1.07% | +8.60% | +12.97% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.97% | 499M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.38% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding